Study: Some “brain-boosting” supplements sold in the US contain not-approved drugs at supratherapeutic doses, exposing users to unknown side effects

In this study, we found supplements with individual doses of piracetam exceeding 1500 mg, and daily doses greater than 11000 mg. Adverse effects of piracetam at pharmaceutical dosages include anxiety, insomnia, agitation, depression, drowsiness, and weight gain. The risks of piracetam in over-the-counter supplements at supratherapeutic dosages, particularly in elderly consumers with renal insufficiency, are unknown … Our findings demonstrate that even after the FDA rejected an application to market piracetam as a new supplement ingredient, the drug was nevertheless introduced into the marketplace. Despite FDA warning letters, the products remain on the market. Until the law governing supplements is reformed such that products adulterated with drugs can be effectively removed from the market, clinicians should advise patients that supplements marketed as cognitive enhancers may contain prohibited drugs at supratherapeutic doses. The Study in Context: AARP: A majority of Americans believe dietary supplements improve brain health, despite the lack of evidence The FDA cracks down on dozens of supplements claiming to prevent or cure Alzheimer’s Disease Solving the Brain Fitness Puzzle Is the Key to Self-Empowered Aging ? Navigating the Brain/ Mind Innovation Landscape &Book presentation El Cerebro Que Cura (The Brain That Heals) from SharpBrains
Source: SharpBrains - Category: Neuroscience Authors: Tags: Cognitive Neuroscience Education & Lifelong Learning age brain fog brain-boosting brain-boosting supplements cognitive--disorders cognitive-enhancement dementia dietary supplements FDA kidney function piracetam Source Type: blogs

Related Links:

Major Depression — the clinical type — is not a normal part of aging. Though it can appear at any age, older adults are at an increased risk. The Centers for Disease Control and Prevention (CDC) distinguishes this condition from having “the blues” and likens it to other medical illnesses that are treatable, like diabetes or hypertension. Overwhelming sadness and anxiety can last for weeks at a time or much longer, with a wide range of other discouraging symptoms. Yet, there are things that can help.  Statistics tell us that later in life, at least one chronic disease will affect 80 percent of u...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Aging Depression depression risk Elderly seniors Source Type: blogs
ConclusionsA history of MST is common among older women veterans and associated with a range of medical and mental health diagnoses. These findings call attention to the need for additional research in this understudied population, and the importance of trauma-informed care approaches for women across the lifespan.
Source: Journal of General Internal Medicine - Category: Internal Medicine Source Type: research
The UK market for cannabidiol, a compound found in cannabis, will soon be worth £1bn. But consumers are being connedRoll up, roll up, ladies and gentleman, and gather around. Do you, your loved one – or family pet – suffer from any of the following conditions? Cancer, epilepsy, diabetes, arthritis, anxiety, menstrual cramps, insomnia, dry skin, psychosis, Alzheimer’s, dementia, anger, depression, ADHD, Crohn’s and IBS, PTSD, opiate addiction, Parkinson’s, pain of any kind, migraine, or canine uptightness? Then it’s your lucky day.Related:CBD: a marijuana miracle or just another hea...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Cannabis Drugs Society Health Medicine Science Pharmaceuticals industry Business Source Type: news
Conclusions: The use of antidepressants, especially SNRIs, was associated with a shorter survival time of sCJD patients. The possible changes in neurotransmitters should be emphasized. Scientifically, this study may provide insights into the mechanism of CJD. Clinically, it may contribute to the early diagnosis of CJD.IntroductionDepression is common in the elderly. Its prevalence rate is as high as 11.19%, and this increases progressively with worsening cognitive impairment (1). The presence of depression is an acknowledged risk factor for dementia (2); it can even double the risk for Alzheimer’s disease (AD) (3, 4)...
Source: Frontiers in Psychiatry - Category: Psychiatry Source Type: research
Sandip T. Auti and Yogesh A. Kulkarni* Shobhaben Pratapbhai Patel School of Pharmacy &Technology Management, SVKM's NMIMS, Mumbai, India Acetylcholinesterase (AChE) is an enzyme involved in the progression of Alzheimer's disease (AD). Cardamom oil (CO) has been reported to have acetylcholinesterase inhibitory, antioxidant and anti-anxiety effects. Hence, we studied the effect of cardamom oil in aluminum chloride induced neurotoxicity in rats. AD like symptoms were induced in Wistar rats with aluminum chloride (100 mg/kg, p.o.). Cardamom oil was administered concomitantly by oral route at doses...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Karin Meissner1,2*, Nicola Talsky1, Elisabeth Olliges1,2, Carmen Jacob1,3,4, Oliver J. Stötzer5, Christoph Salat5, Michael Braun6 and Raluca Flondor1 1Institute of Medical Psychology, Faculty of Medicine, LMU Munich, Munich, Germany 2Division of Health Promotion, Coburg University of Applied Sciences, Coburg, Germany 3Clinical Neurosciences, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom 4Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom 5Haematology and Oncology, Outpatient Cancer Ca...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusions Dysautonomic symptoms frequently occuring in α-synucleinopathies comprise cardiovascular, gastrointestinal, urogenital and thermoregulatory disturbances. These symptoms reduce quality of life and worsen prognosis. The understanding of their pathophysiology, as well as the detection of α-synuclein deposition and autonomic dysfunction in the premotor stages of α-synucleinopathies may be key for identifying novel treatment targets and improving clinical outcomes. While causative treatment is not yet available, improvement of quality of life can be achieved by personalized symptomatic treatment r...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
This study aims to validate an ambulatory circadian monitoring (ACM) device for the detection of sleep and wake states and apply it to the evaluation of sleep quality in patients with Parkinson disease (PD). A polysomnographic validation study was conducted on a group of patients with different sleep disorders in a preliminary phase, followed by a pilot study to apply this methodology to PD patients. The ACM device makes it possible to estimate the main sleep parameters very accurately, as demonstrated by: (a) the lack of significant differences between the mean values detected by PSG and ACM in time in bed (TIB), total sl...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
“To die, to sleep — perchance to dream — ay, there’s the rub, for in this sleep of death what dreams may come…” – William Shakespeare, Hamlet Everyone requires sleep in order to function properly. Sleep is known to aid in healing, in memory formation, reducing stress, eliminating toxins – literally wiping the slate clean of the day’s experiences to begin anew. The subject of decades of research, sleep science continues to amass evidence of new health benefits from sleep. A Single Gene Ties Sleep to Immunity A newly discovered single gene, called nemuri, increase...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Agitation Anger Memory and Perception Psychology Research Sleep Anger Management Circadian Rhythm Immune Function Insomnia nemuri nightmare disorder Nightmares Sleep Apnea Sleep Disorder sleep quality Source Type: blogs
CONCLUSION: The study emphasizes the identification of factors associated with the prescription of PIMs during the first completed comprehensive geriatric assessment. Targeted strategies to reduce modifiable factors associated with the prescription of PIMs in subsequent assessments has the potential to improve medication management in older adults. PMID: 30380343 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Anxiety | Brain | Complementary Medicine | Dementia | Depression | Diets | Education | Harvard | Insomnia | Internal Medicine | Learning | Legislation | Neurology | Neuroscience | Nutrition | Study | Universities & Medical Training | Urology & Nephrology | Warnings | Weight Loss